Estimation of Symptomatic Respiratory Syncytial Virus Infection Incidence in Adults in Multiple Countries: A Time-Series Model-Based Analysis Protocol
- PMID: 38499832
- PMCID: PMC11058168
- DOI: 10.1007/s40121-024-00948-9
Estimation of Symptomatic Respiratory Syncytial Virus Infection Incidence in Adults in Multiple Countries: A Time-Series Model-Based Analysis Protocol
Abstract
Introduction: Estimating respiratory syncytial virus (RSV) burden in adults is challenging because of non-specific symptoms, infrequent standard-of-care testing, resolution of viral shedding before seeking medical care, test positivity that varies by specimen site in the upper airway and lower diagnostic test sensitivity compared to children. Conducting prospective observational studies to assess RSV burden in adults is time- and resource-intensive. Thus, model-based approaches can be applied using existing data to obtain more accurate estimates of RSV burden. This protocol establishes essential elements for estimating RSV incidence rate in adults using a time series model-based approach. It can be tailored to specific databases and applied globally across countries, enabling estimation of local RSV disease burden to inform public health decision-making, including immunization policy.
Methods: Data are analysed using a quasi-Poisson regression model, considering the effect of baseline trends and pathogen co-circulation, stratified by age and risk status. Pathogen co-circulation is represented by viral proxies defined based on ICD code groupings indicating RSV and influenza-specific hospitalizations, lagged 0 up to 4 weeks based on the model selection. A final model is constructed in two steps: optimization of the time trend (using p-values) and selection of the viral proxy lag time (using test statistics, to prioritize the most biologically plausible option). The yearly incidence rate and percentage of events attributable to RSV are estimated from the final model. Confidence intervals are calculated using residual bootstrapping.
Planned outcomes: Outcomes to be modelled are based on administrative ICD code groupings and include the number of cardiorespiratory, respiratory and cardiovascular events in a specific care setting (e.g., general practitioner visit, emergency department visit, hospitalization and death). Cardiovascular events are limited to those for which existing evidence suggests an association with RSV infection. Additional secondary outcomes are constructed as a subset of the primary outcomes based on specific ICD code groups.
Keywords: Disease burden; Emergency department visits; General practitioner visits; Hospitalization; Mortality; Respiratory syncytial virus; Time series analysis.
© 2024. Pifzer.
Conflict of interest statement
Aleksandra Polkowska-Kramek, Robin Bruyndonckx and Thao Mai Phuong Tran are employees of P95 Epidemiology and Pharmacovigilance, which received funding from Pfizer to develop this protocol and manuscript. Elizabeth Begier, Caihua Liang, Charles Nuttens and Bradford D. Gessner are Pfizer employees and may own Pfizer stock.
Similar articles
-
A Model-Based Estimation of RSV-Attributable Incidence of Hospitalizations and Deaths in Italy Between 2015 and 2019.Infect Dis Ther. 2024 Nov;13(11):2319-2332. doi: 10.1007/s40121-024-01041-x. Epub 2024 Sep 18. Infect Dis Ther. 2024. PMID: 39289329 Free PMC article.
-
Estimated Incidence of Hospitalizations Attributable to RSV Infection Among Adults in Ontario, Canada, Between 2013 and 2019.Infect Dis Ther. 2024 Sep;13(9):1949-1962. doi: 10.1007/s40121-024-01018-w. Epub 2024 Jul 15. Infect Dis Ther. 2024. PMID: 39004648 Free PMC article.
-
Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Australia Between 2010 and 2019.Influenza Other Respir Viruses. 2025 Apr;19(4):e70092. doi: 10.1111/irv.70092. Influenza Other Respir Viruses. 2025. PMID: 40254721 Free PMC article.
-
Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.J Infect Dis. 2023 Jul 14;228(2):173-184. doi: 10.1093/infdis/jiad012. J Infect Dis. 2023. PMID: 36661222 Free PMC article.
-
Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.BMC Infect Dis. 2024 Aug 20;24(1):844. doi: 10.1186/s12879-024-09758-3. BMC Infect Dis. 2024. PMID: 39164625 Free PMC article.
Cited by
-
A Model-Based Estimation of RSV-Attributable Incidence of Hospitalizations and Deaths in Italy Between 2015 and 2019.Infect Dis Ther. 2024 Nov;13(11):2319-2332. doi: 10.1007/s40121-024-01041-x. Epub 2024 Sep 18. Infect Dis Ther. 2024. PMID: 39289329 Free PMC article.
-
Estimated Incidence of Hospitalizations Attributable to RSV Infection Among Adults in Ontario, Canada, Between 2013 and 2019.Infect Dis Ther. 2024 Sep;13(9):1949-1962. doi: 10.1007/s40121-024-01018-w. Epub 2024 Jul 15. Infect Dis Ther. 2024. PMID: 39004648 Free PMC article.
-
Estimated Incidence Rate of Specific Types of Cardiovascular and Respiratory Hospitalizations Attributable to Respiratory Syncytial Virus Among Adults in Germany Between 2015 and 2019.Influenza Other Respir Viruses. 2025 May;19(5):e70097. doi: 10.1111/irv.70097. Influenza Other Respir Viruses. 2025. PMID: 40289699 Free PMC article.
-
Health Technology Assessment del vaccino ricombinante adiuvato contro il virus respiratorio sinciziale (Arexvy®).J Prev Med Hyg. 2024 Jun 30;65(2 Suppl 1):E1-E159. doi: 10.15167/2421-4248/jpmh2024.65.2s1. eCollection 2024 Sep. J Prev Med Hyg. 2024. PMID: 39554593 Free PMC article. Italian. No abstract available.
-
Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Australia Between 2010 and 2019.Influenza Other Respir Viruses. 2025 Apr;19(4):e70092. doi: 10.1111/irv.70092. Influenza Other Respir Viruses. 2025. PMID: 40254721 Free PMC article.
References
LinkOut - more resources
Full Text Sources